Zhang Zhenlong, Pan Xiaojie, Qiu Hanfan, Guo Tianxing, Ou Debin, Ding Hang
Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou Fujian 350001, P.R.China.
Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou Fujian 350001,
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2017 Feb 15;31(2):231-234. doi: 10.7507/1002-1892.201610036.
To summarize the clinical experience of vascular repair and reconstruction for treating superior vena cava syndrome (SVCS) caused by thoracic tumor.
Between October 2008 and June 2016, 26 patients with thoracic tumor and SVCS were admitted. There were 18 males and 8 females, aged from 27 to 70 years (mean, 45.9 years). Tumor was typed as B1-B3 thymoma in 13 cases, thymic carcinoma in 6 cases, large B-cell lymphoma in 3 cases, T lymphocytic lymphoma in 1 case, malignant teratoma in 1 case, right lung squamous cell carcinoma in 1 case, and carcinoid in 1 case. The tumor diameter ranged from 8 to 15 cm with an average of 10 cm. The patients had different degrees of neck, face, and upper extremity edema, jugular vein distention, and chest wall collateral venous filling. The superior vena cava pressure was 2.45-5.39 kPa. After excision of tumor and invading superior vena cava, 7 patients underwent superior vena cava reconstruction and 19 patients underwent artificial vascular replacement.
There was no perioperative death, and the symptoms of superior vena cava obstruction were eliminated. Postoperative pulmonary infection, respiratory muscle weakness, and right chylothorax occurred in 4 cases, 1 case, and 1 case respectively. Twenty-four patients were followed up 2-92 months (mean, 37 months), and 2 patients failed to be followed up. At 1, 3, and 5 years, the survival rate was 83.3% (20/24), 41.7% (10/24), and 25% (6/24), respectively. In 6 patients with 5-year survival, there were 1 case of type B1 thymoma, 3 cases of type B3 thymoma, and 2 cases of large B-cell lymphoma.
For preoperative evaluation of SVCS caused by resectable thoracic tumors, vascular repair and recons-truction technique can be used to quickly and effectively relieve the clinical symptoms and improve the quality of life.
总结血管修复重建术治疗胸段肿瘤所致上腔静脉综合征(SVCS)的临床经验。
2008年10月至2016年6月,收治26例胸段肿瘤合并SVCS患者。其中男性18例,女性8例,年龄27~70岁(平均45.9岁)。肿瘤类型为B1~B3型胸腺瘤13例,胸腺癌6例,大B细胞淋巴瘤3例,T淋巴细胞淋巴瘤1例,恶性畸胎瘤1例,右肺鳞状细胞癌1例,类癌1例。肿瘤直径8~15 cm,平均10 cm。患者均有不同程度的颈、面及上肢水肿,颈静脉怒张,胸壁静脉侧支循环充盈。上腔静脉压力为2.45~5.39 kPa。肿瘤及侵犯的上腔静脉切除后,7例行上腔静脉重建,19例行人工血管置换。
围手术期无死亡病例,上腔静脉梗阻症状均消失。术后发生肺部感染4例,呼吸肌无力1例,右侧乳糜胸1例。24例患者获随访2~92个月(平均37个月),2例失访。1年、3年和5年生存率分别为83.3%(20/24)、41.7%(10/24)和25%(6/24)。5年生存的6例患者中,B1型胸腺瘤1例,B3型胸腺瘤3例,大B细胞淋巴瘤2例。
对于可切除胸段肿瘤所致SVCS的术前评估,血管修复重建技术可快速有效地缓解临床症状,提高生活质量。